Impact News +++ CORRECT: 3i Group′s Action sees US expansion, first quarter sales grow (Alliance) +++ 3I GROUP Aktie -3,38%

RECORDATI Aktie

>RECORDATI Aktienkurs

49.24 EUR +6.7% (TradegateBSX)

Ask: 50.6 EUR / 0 Stück

Bid: 50.4 EUR / 0 Stück

Tagesumsatz: 33 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

RECORDATI Aktie über LYNX handeln

Intraday

1 Jahr

>RECORDATI Performance

1 Woche: +3,5%

1 Monat: -4,8%

3 Monate: -5,8%

6 Monate: -9,5%

1 Jahr: -14,3%

laufendes Jahr: -5,0%

>RECORDATI Aktie

Name:

RECORDATI SPA EO -,125

Land:

Italien

Sektor:

Gesundheit

ISIN/ Wkn:

IT0003828271 / A0EABR

Symbol/ Ticker:

RER1 (Frankfurt)

Kürzel:

FRA:RER1, ETR:RER1, RER1:GR

Index:

FTSEMIB

Webseite:

http://www.recordati.it/

Profil:

Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical company specializing in the development, manufacturing, and commercialization of innovative medicines across specia..
>Volltext..

Marktkapitalisierung:

9338.37 Mio. EUR

Unternehmenswert:

9338.37 Mio. EUR

Umsatz:

2649.82 Mio. EUR

EBITDA:

Nettogewinn:

448.92 Mio. EUR

Gewinn je Aktie:

2.17 EUR

Schulden:

Liquide Mittel:

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

11.82%

Gewinnwachstum:

6.5%

Dividende je Aktie:

1.3 EUR

Dividendenrendite:

2.87%

Dividendenschätzung:

2.96%

Div. Historie:

24.11.25 - 0.63€
19.05.25 - 0.67€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

RECORDATI

Letzte Datenerhebung:

26.03.26

>RECORDATI Kennzahlen

Aktien/ Unternehmen:

Aktien: 204.56 Mio. St.

Frei handelbar: 51.68%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 29.08%

Bewertung:

KGV: -

KGV lG: 14.28

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: 16.94%

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>RECORDATI Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>RECORDATI Chart & Kurs - Tradegate

>RECORDATI News

26.03.26 - 13:01	CVC Capital Partners strebt vollständige Übernahme von Recordati an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.02.26 - 19:36	Recordati reports FY2025 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.02.26 - 18:21	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5% (GlobeNewswire EN)
	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA +14.5%, ADJUSTED NET INCOME +14.5%...

12.02.26 - 14:02	Barclays upgrades Recordati to “equal weight” as CVC share overhang risks ease (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.02.26 - 13:06	Recordati shares rise as Kepler upgrades to “buy” on attractive valuation (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.01.26 - 09:01	Recordati und Moderna kooperieren bei Therapie für seltene Erbkrankheit/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.01.26 - 23:21	RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA (GlobeNewswire EN)
	RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA...

29.01.26 - 23:06	Moderna, Inc.: Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (Accesswire)
	Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition t......

13.01.26 - 14:48	Recordati Launches Isturisa In Canada For Cushing′s Disease (AFX)
	ROME (dpa-AFX) - Recordati Rare Diseases Canada, a unit of Recordati (REC.MI) on Tuesday announced that Isturisa, for the treatment of Cushing's disease, is now available in Canada. The launch fol......

09.12.25 - 13:33	Recordati Rare Diseases Announces Real-World Data on Long-Term Safety of ENJAYMO® (sutimlimab-jome) in Cold Agglutinin Disease and Cold Agglutinin Syndrome (CAD/CAS) at American Society of Hematology (ASH) Annual Meeting (PR Newswire)
	Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment duration of more than two years ENJAYMO® is approved for treatment of hemolysis......

08.12.25 - 13:33	Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting (PR Newswire)
	Poster presentations highlight AI-driven CD histopathology grading technology; morbidity and financial burden of idiopathic multicentric CD (iMCD); severity of pediatric iMCD; and CD subtype classification BRIDGEWATER, N.J., Dec. 8, 2025 /PRNewswire/ -- Recordati Rare Diseases Inc. today......

12.11.25 - 08:04	Recordati doubles Isturisa sales forecast, keeps 2027 targets amid higher spending (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 04:48	Recordati 9-month Profit Down 3.6%; Upgrades Peak Year Sales Expectations For Isturisa (AFX)
	ROME (dpa-AFX) - Recordati S.p.A. (RCDTF.PK) a pharmaceutical company, reported that its net income attributable to equity holders of the parent for the first nine months of 2025 was 326.29 millio......

11.11.25 - 20:30	RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION (GlobeNewswire EN)
	NEWS RELEASE...

03.11.25 - 19:33	Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting (PR Newswire)
	Poster presentations at ASH highlight advances in the understanding and research of Castleman disease, cold agglutinin disease, B-cell lymphoma, and other hematologic conditions BRIDGEWATER, N.J., Nov. 3, 2025 /PRNewswire/ -- Recordati Rare Diseases Inc. today announced the presentation......

29.10.25 - 15:27	Amarin outlines accelerated path to positive free cash flow in 2026 supported by Recordati partnership and $70M OpEx savings (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.10.25 - 08:36	RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER (GlobeNewswire EN)
	NEWS RELEASE...

21.10.25 - 14:54	Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology (GlobeNewswire EN)
	Milan, 21st October 2025 – Recordati S.p.A. today announced the launch of the 12th edition of the Arrigo Recordati Prize, dedicated to advancing research in paediatric oncology, with a focus on sarcomas. Paediatric sarcomas are among the leading causes of cancer-related death in children and continue to take a profound toll on the children and families affected by the disease....

11.08.25 - 12:03	Recordati shares rise after Jefferies upgrade to “buy” on growth prospects (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.25 - 20:12	Amarin targets $70M cost savings and accelerates VAZKEPA European expansion through Recordati partnership (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: So wertlos ist keiner, daß er nicht wenigstens als schlechtes Beispiel herhalten könnte. - Markus M. Ronner

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram